Pathophysiological roles of osteoprotegerin (OPG)

European Journal of Cell Biology

Volumn 88, Issue 1, 2009, Pages 1-17

  Reid, Penny ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Osteoprotegerin; Tumourigenesis; Vascular disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; IBANDRONIC ACID; OSTEOPROTEGERIN; PAMIDRONIC ACID; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELL PROTECTION; CELL SPECIFICITY; CELL SURVIVAL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG MECHANISM; ENDOTHELIUM CELL; ENTERITIS; GENE MUTATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIODONTITIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL; UPREGULATION;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE DISEASES; CELL SURVIVAL; HUMANS; IMMUNE SYSTEM; NEOPLASMS; OSTEOPROTEGERIN; RANK LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR DISEASES;

EID: 57249094356     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2008.06.004     Document Type: Short Survey

References (142)

1. Ahlen J., Andersson S., Mukohyama H., Roth C., Backman A., Conaway H.H., and Lerner U.H. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 31 (2002) 242-251
2. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 (2003) 337-348
3. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., and Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
4. Arenillas J.F., and Alvarez-Sabin J. Basic mechanisms in intracranial large-artery atherosclerosis: advances and challenges. Cerebrovasc. Dis. 20 Suppl. 2 (2005) 75-83
5. Armstrong A.P., Tometsko M.E., Glaccum M., Sutherland C.L., Cosman D., and Dougall W.C. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem. 277 (2002) 44347-44356
6. Asanuma Y., Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., Shintani A., Raggi P., Sokka T., Pincus T., and Stein C.M. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 195 (2007) 135-141
7. Ashcroft A.J., Cruickshank S.M., Croucher P.I., Perry M.J., Rollinson S., Lippitt J.M., Child J.A., Dunstan C., Felsburg P.J., Morgan G.J., and Carding S.R. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19 (2003) 849-861
8. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11 (2001) 372-377
9. Baud'huin M., Duplomb L., Ruiz Velasco C., Fortun Y., Heymann D., and Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev. Anticancer Ther. 7 (2007) 221-232
10. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16 (2001) 348-360
11. Ben-Tal Cohen E., Hohensinner P.J., Kaun C., Maurer G., Huber K., and Wojta J. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem. Pharmacol. 73 (2007) 77-83
12. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., Averill M., Schwartz S.M., Giachelli C.M., and Rosenfeld M.E. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2117-2124
13. Borset M., Hjertner O., Yaccoby S., Epstein J., and Sanderson R.D. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96 (2000) 2528-2536
14. Bostanci N., Ilgenli T., Emingil G., Afacan B., Han B., Toz H., Atilla G., Hughes F.J., and Belibasakis G.N. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J. Clin. Periodontol. 34 (2007) 370-376
15. Brandstrom H., Gerdhem P., Stiger F., Obrant K.J., Melhus H., Ljunggren O., Kindmark A., and Akesson K. Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. Calcif. Tissue Int. 74 (2004) 18-24
16. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., and Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
17. Catrina A.I., af Klint E., Ernestam S., Catrina S.B., Makrygiannakis D., Botusan I.R., Klareskog L., and Ulfgren A.K. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. 54 (2006) 76-81
18. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., and Rabbani S.A. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107 (2006) 289-298
19. Cheung J., Mak Y.T., Papaioannou S., Evans B.A., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177 (2003) 423-433
20. Chong B., Hegde M., Fawkner M., Simonet S., Cassinelli H., Coker M., Kanis J., Seidel J., Cristina T., Tuysuz B., Yuksel B., Love D., and Cundy T. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J. Bone Miner. Res. 18 (2003) 2095-2104
21. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95 (2004) 1046-1057
22. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., and Osdoby P. Receptor activator of NF-kappaB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276 (2001) 20659-20672
23. Corey E., Brown L.G., Kiefer J.A., Quinn J.E., Pitts T.E., Blair J.M., and Vessella R.L. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65 (2005) 1710-1718
24. Cross S.S., Yang Z., Brown N.J., Balasubramanian S.P., Evans C.A., Woodward J.K., Neville-Webbe H.L., Lippitt J.M., Reed M.W., Coleman R.E., and Holen I. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int. J. Cancer 118 (2006) 1901-1908
25. Crotti T., Smith M.D., Hirsch R., Soukoulis S., Weedon H., Capone M., Ahern M.J., and Haynes D. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodontal Res. 38 (2003) 380-387
26. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., Brabbs A.C., van Beek E.J., Holen I., Skerry T.M., Dunstan C.R., Russell G.R., Van Camp B., and Vanderkerken K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98 (2001) 3534-3540
27. Cundy T., Hegde M., Naot D., Chong B., King A., Wallace R., Mulley J., Love D.R., Seidel J., Fawkner M., Banovic T., Callon K.E., Grey A.B., Reid I.R., Middleton-Hardie C.A., and Cornish J. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11 (2002) 2119-2127
28. Cundy T., Davidson J., Rutland M.D., Stewart C., and DePaoli A.M. Recombinant osteoprotegerin for juvenile Paget's disease. N. Engl. J. Med. 353 (2005) 918-923
29. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., and Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115 (2002) 4317-4325
30. Dobnig H., Hofbauer L.C., Viereck V., Obermayer-Pietsch B., and Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis Int. 17 (2006) 693-703
31. Dougall W.C., and Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25 (2006) 541-549
32. Eaton C.L., Wells J.M., Holen I., Croucher P.I., and Hamdy F.C. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59 (2004) 304-310
33. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
34. Feuerherm A.J., Borset M., Seidel C., Sundan A., Leistad L., Ostensen M., and Faxvaag A. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol. 30 (2001) 229-234
35. Fisher J.L., Thomas-Mudge R.J., Elliott J., Hards D.K., Sims N.A., Slavin J., Martin T.J., and Gillespie M.T. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66 (2006) 3620-3628
36. Geusens P.P., Landewe R.B., Garnero P., Chen D., Dunstan C.R., Lems W.F., Stinissen P., van der Heijde D.M., van der Linden S., and Boers M. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 54 (2006) 1772-1777
37. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
38. Glantschnig H., Fisher J.E., Wesolowski G., Rodan G.A., and Reszka A.A. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10 (2003) 1165-1177
39. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., and Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189 (1999) 1343-1354
40. Guldiken B., Guldiken S., Turgut B., Turgut N., Demir M., Celik Y., Arikan E., and Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb. Res. 120 (2007) 511-516
41. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
42. Heath D.J., Vanderkerken K., Cheng X., Gallagher O., Prideaux M., Murali R., and Croucher P.I. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 67 (2007) 202-208
43. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250 (1998) 776-781
44. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., and Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
45. Holen I., and Shipman C.M. Role of osteoprotegerin (OPG) in cancer. Clin. Sci. (London) 110 (2006) 279-291
46. Holen I., Croucher P.I., Hamdy F.C., and Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62 (2002) 1619-1623
47. Holen I., Cross S.S., Neville-Webbe H.L., Cross N.A., Balasubramanian S.P., Croucher P.I., Evans C.A., Lippitt J.M., Coleman R.E., and Eaton C.L. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival?. Breast Cancer Res. Treat. 92 (2005) 207-215
48. Horwood N.J., Elliott J., Martin T.J., and Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139 (1998) 4743-4746
49. Janssens K., de Vernejoul M.C., de Freitas F., Vanhoenacker F., and Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone 36 (2005) 542-548
50. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., and Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 (2002) 1192-1194
51. Jung K., Lein M., Stephan C., Von Hosslin K., Semjonow A., Sinha P., Loening S.A., and Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 111 (2004) 783-791
52. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., and Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
53. Kobayashi-Sakamoto M., Hirose K., Isogai E., and Chiba I. NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem. Biophys. Res. Commun. 315 (2004) 107-112
54. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., and Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
55. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr. Opin. Pharmacol. 5 (2005) 618-625
56. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
57. Lawrie A., Waterman E., Southwood M., Evans D., Suntharalingam J., Francis S., Crossman D., Croucher P., Morrell N., and Newman C. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am. J. Pathol. 172 (2008) 256-264
58. Lipton A., Ali S.M., Leitzel K., Chinchilli V., Witters L., Engle L., Holloway D., Bekker P., and Dunstan C.R. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res. 8 (2002) 2306-2310
59. Littlewood T.D., and Bennett M.R. Apoptotic cell death in atherosclerosis. Curr. Opin. Lipidol. 14 (2003) 469-475
60. MacFarlane M., Merrison W., Dinsdale D., and Cohen G.M. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J. Cell Biol. 148 (2000) 1239-1254
61. Makiishi-Shimobayashi C., Tsujimura T., Iwasaki T., Yamada N., Sugihara A., Okamura H., Hayashi S., and Terada N. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. 281 (2001) 361-366
62. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., and Giachelli C.M. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 275 (2000) 20959-20962
63. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., and Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
64. Martini G., Gennari L., Merlotti D., Salvadori S., Franci M.B., Campagna S., Avanzati A., De Paola V., Valleggi F., and Nuti R. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40 (2007) 457-463
65. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J. Biol. Chem. 275 (2000) 31155-31161
66. Messalli E.M., Mainini G., Scaffa C., Cafiero A., Salzillo P.L., Ragucci A., and Cobellis L. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 56 (2007) 38-44
67. Mezquita-Raya P., de la Higuera M., Garcia D.F., Alonso G., Ruiz-Requena M.E., de Dios Luna J., Escobar-Jimenez F., and Munoz-Torres M. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporosis Int. 16 (2005) 1368-1374
68. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P.J., Lacey D.L., Boyle W.J., and Simonet W.S. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192 (2000) 463-474
69. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., and Tanaka S. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J. Cell Biol. 148 (2000) 333-342
70. Mogi M., Otogoto J., Ota N., and Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J. Dent. Res. 83 (2004) 166-169
71. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., and Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61 (2001) 4432-4436
72. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., Stolina M., Kostenuik P.J., and Demer L.L. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117 (2008) 411-420
73. Mossetti G., Rendina D., De Filippo G., Viceconti R., Di Domenico G., Cioffi M., Postiglione L., and Nunziata V. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 36 (2005) 549-554
74. Mountzios G., Dimopoulos M.A., Bamias A., Papadopoulos G., Kastritis E., Syrigos K., Pavlakis G., and Terpos E. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46 (2007) 221-229
75. Nakagawa N., Yasuda H., Yano K., Mochizuki S., Kobayashi N., Fujimoto H., Shima N., Morinaga T., Chikazu D., Kawaguchi H., and Higashio K. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 265 (1999) 158-163
76. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., and Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275 (2000) 768-775
77. Neville-Webbe H.L., Cross N.A., Eaton C.L., Nyambo R., Evans C.A., Coleman R.E., and Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86 (2004) 269-279
78. Nguyen K.Q., Olesen P., Ledet T., and Rasmussen L.M. Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. Endocrine 32 (2007) 52-58
79. Nyambo R., Cross N., Lippitt J., Holen I., Bryden G., Hamdy F.C., and Eaton C.L. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res. 19 (2004) 1712-1721
80. Olesen P., Nguyen K., Wogensen L., Ledet T., and Rasmussen L.M. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1058-H1064
81. Ouaaz F., Arron J., Zheng Y., Choi Y., and Beg A.A. Dendritic cell development and survival require distinct NF-κB subunits. Immunity 16 (2002) 257-270
82. Palmqvist P., Persson E., Conaway H.H., and Lerner U.H. IL-6, leukaemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169 (2002) 3353-3362
83. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., and Choi Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98 (2001) 11581-11586
84. Pettersen I., Bakkelund W., Smedsrod B., and Sveinbjornsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 25 (2005) 3809-3816
85. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1610-1616
86. Pritzker L.B., Scatena M., and Giachelli C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 15 (2004) 2834-2841
87. Rattazzi M., Bennett B.J., Bea F., Kirk E.A., Ricks J.L., Speer M., Schwartz S.M., Giachelli C.M., and Rosenfeld M.E. Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: potential role of chondrocyte-like cells. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1420-1425
88. Redlich K., Gortz B., Hayer S., Zwerina J., Doerr N., Kostenuik P., Bergmeister H., Kollias G., Steiner G., Smolen J.S., and Schett G. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am. J. Pathol. 164 (2004) 543-555
89. Rhee E.J., Lee W.Y., Kim S.Y., Kim B.J., Sung K.C., Kim B.S., Kang J.H., Oh K.W., Oh E.S., Baek K.H., Kang M.I., Woo H.Y., Park H.S., Kim S.W., Lee M.H., and Park J.R. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin. Sci. (London) 108 (2005) 237-243
90. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J. Clin. Endocrinol. Metab. 87 (2002) 4470-4475
91. Rubin J., Ackert-Bicknell C.L., Zhu L., Fan X., Murphy T.C., Nanes M.S., Marcus R., Holloway L., Beamer W.G., and Rosen C.J. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J. Clin. Endocrinol. Metab. 87 (2002) 4273-4279
92. Schett G., Middleton S., Bolon B., Stolina M., Brown H., Zhu L., Pretorius J., Zack D.J., Kostenuik P., and Feige U. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum. 52 (2005) 1604-1611
93. Schneeweis L.A., Willard D., and Milla M.E. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J. Biol. Chem. 280 (2005) 41155-41164
94. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., and Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 88 (2003) 1024-1028
95. Schoppet M., Henser S., Ruppert V., Stubig T., Al-Fakhri N., Maisch B., and Hofbauer L.C. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J. Cell. Biochem. 100 (2007) 1430-1439
96. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., Celeghini C., Capitani S., and Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 169 (2006) 2236-2244
97. Secchiero P., Corallini F., Rimondi E., Chiaruttini C., di Iasio M.G., Rustighi A., Del Sal G., and Zauli G. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood 111 (2008) 1287-1294
98. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
99. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63 (2003) 912-916
100. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
101. Soufi M., Schoppet M., Sattler A.M., Herzum M., Maisch B., Hofbauer L.C., and Schaefer J.R. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J. Clin. Endocrinol. Metab. 89 (2004) 3764-3768
102. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., Borset M., and Sundan A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100 (2002) 3002-3007
103. Takai H., Kanematsu M., Yano K., Tsuda E., Higashio K., Ikeda K., Watanabe K., and Yamada Y. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273 (1998) 27091-27096
104. Takayanagi H., Oda H., Yamamoto S., Kawaguchi H., Tanaka S., Nishikawa T., and Koshihara Y. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240 (1997) 279-286
105. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., and Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 259-269
106. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., and Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195 (2002) 161-169
107. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., Agnusdei D., Termine J.D., and Migliaccio S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
108. Tazoe M., Mogi M., Goto S., and Togari A. Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. Arch. Oral Biol. 48 (2003) 615-619
109. Teng Y.T., Nguyen H., Gao X., Kong Y.Y., Gorczynski R.M., Singh B., Ellen R.P., and Penninger J.M. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106 (2000) R59-R67
110. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15 (2004) 457-475
111. Thirunavukkarasu K., Miles R.R., Halladay D.L., Yang X., Galvin R.J., Chandrasekhar S., Martin T.J., and Onyia J.E. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem. 276 (2001) 36241-36250
112. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., and Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 (1999) 4451-4458
113. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., and Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234 (1997) 137-142
114. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., Shinki T., Gillespie M.T., Martin T.J., Higashio K., and Suda T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 (2000) 3478-3484
115. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S.S., Simonsen S., Christensen G., Gullestad L., and Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111 (2005) 2461-2468
116. Valero C., Olmos J.M., Rivera F., Hernandez J.L., Vega M.E., and Macias J.G. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. Calcif. Tissue Int. 78 (2006) 343-347
117. Van Poznak C., Cross S.S., Saggese M., Hudis C., Panageas K.S., Norton L., Coleman R.E., and Holen I. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59 (2006) 56-63
118. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., and Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63 (2003) 287-289
119. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Grundker C., and Hofbauer L.C. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. 291 (2002) 680-686
120. Viereck V., Grundker C., Blaschke S., Niederkleine B., Siggelkow H., Frosch K.H., Raddatz D., Emons G., and Hofbauer L.C. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88 (2003) 4206-4213
121. Vik A., Mathiesen E.B., Noto A.T., Sveinbjornsson B., Brox J., and Hansen J.B. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 191 (2007) 128-134
122. Vitovski S., Phillips J.S., Sayers J.R., and Croucher P.I. Investigating the interaction between osteoprotegerin and RANKL or TRAIL: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282 (2007) 31601-31609
123. Wada N., Maeda H., Tanabe K., Tsuda E., Yano K., Nakamuta H., and Akamine A. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. J. Periodontal Res. 36 (2001) 56-63
124. Wada N., Maeda H., Yoshimine Y., and Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35 (2004) 629-635
125. Wesche H., Korherr C., Kracht M., Falk W., Resch K., and Martin M.U. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J. Biol. Chem. 272 (1997) 7727-7731
126. Whyte M.P. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann. NY Acad. Sci. 1068 (2006) 143-164
127. Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgornik M.N., McAlister W.H., and Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347 (2002) 175-184
128. Whyte M.P., Singhellakis P.N., Petersen M.B., Davies M., Totty W.G., and Mumm S. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B 'Balkan' mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J. Bone Miner. Res. 22 (2007) 938-946
129. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., and Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186 (1997) 2075-2080
130. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., and Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4 (1999) 1041-1049
131. Xing L., Bushnell T.P., Carlson L., Tai Z., Tondravi M., Siebenlist U., Young F., and Boyce B.F. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17 (2002) 1200-1210
132. Yamaguchi K., Kinosaki M., Goto M., Kobayashi F., Tsuda E., Morinaga T., and Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 273 (1998) 5117-5123
133. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K., and Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14 (1999) 518-527
134. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., and Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
135. Yun T.J., Chaudhary P.M., Shu G.L., Frazer J.K., Ewings M.K., Schwartz S.M., Pascual V., Hood L.E., and Clark E.A. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161 (1998) 6113-6121
136. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., Ewings M.E., Mohaupt M., Herring S.W., and Clark E.A. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166 (2001) 1482-1491
137. Zannettino A.C., Holding C.A., Diamond P., Atkins G.J., Kostakis P., Farrugia A., Gamble J., To L.B., Findlay D.M., and Haynes D.R. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J. Cell Physiol. 204 (2005) 714-723
138. Zauli G., Corallini F., Bossi F., Fischetti F., Durigutto P., Celeghini C., Tedesco F., and Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110 (2007) 536-543
139. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., and Keller E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107 (2001) 1235-1244
140. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., and Chen Y.E. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 521 (2002) 180-184
141. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R., Seibel M.J., and Dunstan C.R. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40 (2007) 471-478
142. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., Dunstan C., Kollias G., Steiner G., Smolen J., and Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50 (2004) 277-290